cost-effectiveness

Events

Partner Content

Joint 23rd Medicines for Europe – 20th IGBA Annual Conferenc...

The Joint 23rd Medicines for Europe – 20th IGBA Annual Conference will unite over 300 experts from the generic and biosimilar sectors to discuss market trends, innovative comm

News

Waiting on NICE decision, Pfizer provides breast cancer drug...

NICE rejected Ibrance in initial decision in February.

News

NICE backs Amgen's Blincyto in rare leukaemia

Drug will also be available to children via Cancer Drugs Fund.

News

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

Government wasted £1.3 billion on Cancer Drugs Fund, says st...

The £1.3 billion of public expenditure on the old Cancer Drugs Fund (CDF) did not deliver value to patients or society, according to a new study.

News

UK pharma calls for increased NHS funding ahead of election

NHS funding at heart of pharma's election manifesto.

News

EU regulators back two more orphan drugs, question of pricin...

Two orphan medicines are heading towards the European market, after regulators recommended rare disease drugs from Biogen and BioMarin.

Joint 23rd Medicines for Europe – 20th IGBA Annual Conferenc...

Waiting on NICE decision, Pfizer provides breast cancer drug...

NICE backs Amgen's Blincyto in rare leukaemia

Government wasted £1.3 billion on Cancer Drugs Fund, says st...

UK pharma calls for increased NHS funding ahead of election

EU regulators back two more orphan drugs, question of pricin...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

cost-effectiveness

Editor's Picks